Astellas Pharma Inc 2024 SR
The report outlines Astellas Pharma's environmental, health, and safety (EHS) performance for fiscal 2023. Key highlights include the validation of greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) to align with the 1.5°C goal and a commitment to achieving net-zero emissions by 2050. The company reported a 40% decrease in Scope 1 and 2 emissions compared to the 2015 base year and improved water resource productivity by 65% relative to 2016. Additionally, Astellas completed the treatment of all high-concentrate PCB-contaminated waste and integrated sustainability indicators into executive remuneration.
Company: Astellas Pharma Inc
Sector: Health Care
Country: Japan
Year: 2024
Type: SR
Pages: 25
Astellas Pharma Inc
Ehs Report
The report outlines Astellas Pharma's environmental, health, and safety (EHS) performance for fiscal 2023. Key highlights include the validation of greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) to align with the 1.5°C goal and a commitment to achieving net-zero emissions by 2050. The company reported a 40% decrease in Scope 1 and 2 emissions compared to the 2015 base year and improved water resource productivity by 65% relative to 2016. Additionally, Astellas completed the treatment of all high-concentrate PCB-contaminated waste and integrated sustainability indicators into executive remuneration.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2023
Published
Jul 1, 2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Workplace Fatalities
Net Zero Target
Employees